| Methods |
2‐ to 4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐114 mm Hg after run‐in; 8‐week double‐blind treatment |
| Participants |
All patients: n=165;
Benazepril 20 mg: n=50; baseline sitting SBP=156 mmHg, DBP=103 mm Hg;
Benazepril 40 mg: n=50; baseline sitting SBP=154 mmHg, DBP=102 mm Hg;
Benazepril 80 mg: n=37; baseline sitting SBP=161 mmHg, DBP=104 mm Hg;
Placebo: n=50; baseline sitting SBP=154 mmHg, DBP=103 mm Hg |
| Interventions |
Benazepril 20 mg once daily;
Benazepril 40 mg once daily;
Benazepril 80 mg once daily;
Placebo |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP;
Mean change from baseline in peak sitting SBP/DBP |
| Notes |
BP change reported; SD of change not reported, endpoint BP and SD not reported; imputed overall trial mean SD of change; BP data from abstract; BP measurement device not reported; Jadad score=2; funding source= Ciba‐Geigy Inc. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
